CA2504496C - N-oxides and derivatives of melphalan for treating diseased states associated with hypoxia inducible factor - Google Patents

N-oxides and derivatives of melphalan for treating diseased states associated with hypoxia inducible factor Download PDF

Info

Publication number
CA2504496C
CA2504496C CA2504496A CA2504496A CA2504496C CA 2504496 C CA2504496 C CA 2504496C CA 2504496 A CA2504496 A CA 2504496A CA 2504496 A CA2504496 A CA 2504496A CA 2504496 C CA2504496 C CA 2504496C
Authority
CA
Canada
Prior art keywords
hif
cancer
cells
protein
hypoxia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2504496A
Other languages
English (en)
French (fr)
Other versions
CA2504496A1 (en
Inventor
Lynn Kirkpatrick
Garth Powis
Sarah J. Welsh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prolx Pharmaceuticals Corp
University of Arizona
Original Assignee
Prolx Pharmaceuticals Corp
University of Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prolx Pharmaceuticals Corp, University of Arizona filed Critical Prolx Pharmaceuticals Corp
Publication of CA2504496A1 publication Critical patent/CA2504496A1/en
Application granted granted Critical
Publication of CA2504496C publication Critical patent/CA2504496C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
    • C07F9/65846—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a six-membered ring which may be condensed with another ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2504496A 2002-11-06 2003-11-03 N-oxides and derivatives of melphalan for treating diseased states associated with hypoxia inducible factor Expired - Fee Related CA2504496C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/288,888 2002-11-06
US10/288,888 US20040087556A1 (en) 2002-11-06 2002-11-06 N-oxides and derivatives of melphalan for treating diseased states associated with hypoxia inducible factor
PCT/US2003/035226 WO2004043359A2 (en) 2002-11-06 2003-11-03 N-oxides and derivatives of melphalan for treating diseased states associated with hypoxia inducible factor

Publications (2)

Publication Number Publication Date
CA2504496A1 CA2504496A1 (en) 2004-05-27
CA2504496C true CA2504496C (en) 2010-05-04

Family

ID=32175991

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2504496A Expired - Fee Related CA2504496C (en) 2002-11-06 2003-11-03 N-oxides and derivatives of melphalan for treating diseased states associated with hypoxia inducible factor

Country Status (7)

Country Link
US (2) US20040087556A1 (enExample)
EP (1) EP1567476A4 (enExample)
JP (1) JP2006508124A (enExample)
AU (1) AU2003291282B2 (enExample)
CA (1) CA2504496C (enExample)
MX (1) MXPA05004845A (enExample)
WO (1) WO2004043359A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050049309A1 (en) * 2003-07-14 2005-03-03 Lynn Kirkpatrick Regulation of HIF protein levels via deubiquitination pathway
US20110092595A1 (en) * 2008-02-15 2011-04-21 Garth Powis Compositions and Methods for Treating Lung Cancer
WO2012058325A1 (en) * 2010-10-29 2012-05-03 Oncothyreon Inc. Compounds and methods useful for treatment of diseases mediated by hif-1
WO2012082765A2 (en) 2010-12-16 2012-06-21 The United State Of America. As Represented By The Secretary Department Of Health And Human Services Methods for decreasing body weight and treating diabetes
EP3102195B1 (en) 2014-02-03 2021-10-06 Quadriga Biosciences, Inc. Beta-substituted beta-amino acids and analogs as chemotherapeutic agents
EP3102194A1 (en) 2014-02-03 2016-12-14 Quadriga Biosciences, Inc. Beta-substituted gamma-amino acids and analogs as chemotherapeutic agents
US10349839B2 (en) * 2015-02-27 2019-07-16 Biotronik Se & Co. Implantable pressure sensor device
AR105592A1 (es) 2015-08-03 2017-10-18 Quadriga Biosciences Inc b-AMINOÁCIDOS b-SUSTITUIDOS Y ANÁLOGOS COMO AGENTES QUIMIOTERAPÉUTICOS Y USOS DE LOS MISMOS
US10842812B2 (en) 2015-08-12 2020-11-24 The General Hospital Corporation Compositions and methods that promote hypoxia or the hypoxia response for treatment and prevention of mitochondrial dysfunction and oxidative stress disorders
WO2018160772A1 (en) 2017-02-28 2018-09-07 The United State Of America, As Represented By The Secretary, Department Of Health & Human Services Method of treating obesity, insulin resistance, non-alcoholic fatty liver disease including non-alcoholic steatohepatitis
WO2020146758A1 (en) 2019-01-10 2020-07-16 The General Hospital Corporation Methods to treat mitochondrial-associated dysfunctions or diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602278A (en) * 1994-10-20 1997-02-11 Kirkpatrick; Lynn N-oxides and derivatives of chlorambucil for treating hypoxic tumor cells

Also Published As

Publication number Publication date
WO2004043359B1 (en) 2004-10-28
US7399785B2 (en) 2008-07-15
CA2504496A1 (en) 2004-05-27
AU2003291282A1 (en) 2004-06-03
EP1567476A2 (en) 2005-08-31
EP1567476A4 (en) 2008-09-24
JP2006508124A (ja) 2006-03-09
MXPA05004845A (es) 2005-10-05
US20050026872A1 (en) 2005-02-03
WO2004043359A3 (en) 2004-09-10
AU2003291282B2 (en) 2010-11-11
WO2004043359A2 (en) 2004-05-27
US20040087556A1 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
Koh et al. Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1α
Wang et al. Ferroptosis: A double-edged sword
Dayalan Naidu et al. C151 in KEAP1 is the main cysteine sensor for the cyanoenone class of NRF2 activators, irrespective of molecular size or shape
Dowling et al. Metformin inhibits mammalian target of rapamycin–dependent translation initiation in breast cancer cells
van der Mijn et al. Novel drugs that target the metabolic reprogramming in renal cell cancer
McCubrey et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance
Boengler et al. Inhibition of permeability transition pore opening by mitochondrial STAT3 and its role in myocardial ischemia/reperfusion
CN101842095B (zh) 肿瘤治疗的配方,方法和靶目标
Chen et al. Baicalein reverses hypoxia-induced 5-FU resistance in gastric cancer AGS cells through suppression of glycolysis and the PTEN/Akt/HIF-1α signaling pathway
AU2003291282B2 (en) N-oxides and derivatives of melphalan for treating diseased states associated with hypoxia inducible factor
Han et al. A deep insight into ferroptosis in renal disease: facts and perspectives
EP0831891B1 (en) Oxidant scavengers
US11090266B2 (en) Nanoliposomal c-MYC-siRNA inhibits in vivo tumor growth of cisplatin-resistant ovarian cancer
Chun et al. Phorbol ester stimulates the nonhypoxic induction of a novel hypoxia-inducible factor 1α isoform: implications for tumor promotion
Guo et al. RETRACTED ARTICLE: curcumin inhibits growth of prostate carcinoma via miR-208-mediated CDKN1A activation
Deng et al. Mirk/dyrk1B kinase is upregulated following inhibition of mTOR
EP3639820A1 (en) Flavagline derivatives for inhibition of kras oncogene activation
Ibrahim et al. Induction of the hypoxia-inducible factor system by low levels of heat shock protein 90 inhibitors
Xiao et al. RNF7 inhibits apoptosis and sunitinib sensitivity and promotes glycolysis in renal cell carcinoma via the SOCS1/JAK/STAT3 feedback loop
Peng et al. Mutation of TP53 confers ferroptosis resistance in lung cancer through the FOXM1/MEF2C axis
Oak et al. Curcumin mediates selective aggregation of mutant p53 in cancer cells: A promising therapeutic strategy
Yun et al. Geldanamycin inhibits TGF-β signaling through induction of Hsp70
Masunaga et al. Usefulness of combined treatment with mild temperature hyperthermia and/or tirapazamine in the treatment of solid tumors: its independence of p53 status
Mao et al. DHODH-mediated suppression of ferroptosis supports radioresistance and represents a therapeutic vulnerability in lung cancer
Li et al. Dihydrotanshinone I inhibits the translational expression of hypoxia-inducible factor-1α

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20131105